Unknown

Dataset Information

0

CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report.


ABSTRACT: BACKGROUND:Treatment of steroid resistant nephrotic syndrome is still a challenge for physicians. There are a growing number of studies exploring genetic background of steroid-resistant glomerulopathies. CASE DIAGNOSIS/TREATMENT:We present the case of a 4-year-old girl with steroid-resistant glomerulopathy due to a COQ6 defect with no additional systemic symptoms. The disease did not respond for second-line therapy with calcineurin inhibitor, but it remitted completely after oral treatment with 30 mg/kg/d of coenzyme Q10 (CoQ10). The patient was identified to be a compound heterozygote for two pathogenic variants in COQ6 gene: a known missense substitution c.1078C?>?T (p.R360W) and a novel frameshift c.804delC mutation. After 12 months of CoQ10 therapy, the child remains in full remission, her physical development accelerated, frequent respiratory airways diseases subsided. CONCLUSIONS:Genetic assessment of children with steroid-resistant nephrotic proteinuria enables therapy optimization. Proteinuria caused by a COQ6 gene defect can be successfully treated with CoQ10.

SUBMITTER: Stanczyk M 

PROVIDER: S-EPMC6208703 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report.

Stańczyk Małgorzata M   Bałasz-Chmielewska Irena I   Lipska-Ziętkiewicz Beata B   Tkaczyk Marcin M  

Pediatric nephrology (Berlin, Germany) 20180919 12


<h4>Background</h4>Treatment of steroid resistant nephrotic syndrome is still a challenge for physicians. There are a growing number of studies exploring genetic background of steroid-resistant glomerulopathies.<h4>Case diagnosis/treatment</h4>We present the case of a 4-year-old girl with steroid-resistant glomerulopathy due to a COQ6 defect with no additional systemic symptoms. The disease did not respond for second-line therapy with calcineurin inhibitor, but it remitted completely after oral  ...[more]

Similar Datasets

| S-EPMC7507654 | biostudies-literature
| S-EPMC8494821 | biostudies-literature
| S-EPMC10601732 | biostudies-literature
| S-EPMC11366101 | biostudies-literature
| S-EPMC7791994 | biostudies-literature
| S-EPMC9482153 | biostudies-literature
| S-EPMC9918010 | biostudies-literature
| S-EPMC8206272 | biostudies-literature
| S-EPMC5667876 | biostudies-literature
| S-EPMC8283120 | biostudies-literature